Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

October 3, 2017 First Stable, Serially Transplantable M5 AML PDX Model Published It is traditionally difficult to develop stable blood cancer patient-derived xenograft (PDX) models. Historically, commercially available models have been transient and non-transferable through passages. This only allows one-shot studies providing a gross measure of response, not suitable for efficacy studies. LEARN MORE
September 28, 2017 Impact of Anesthesia During Comprehensive Assessments On Glucose Homeostasis in Diabetic NHPs In the clinic, either an oral glucose (oGTT) or mixed meal (MMTT) tolerance test is used to provide comprehensive ... LEARN MORE
September 26, 2017 Epigenetic Inhibitors: Strategies to Enhance Patient Response to Immunotherapy Major breakthroughs in the treatment of patients with multiple types of cancer have been achieved by drugs targeting ... LEARN MORE
September 21, 2017 Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎ A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on ... LEARN MORE
September 19, 2017 Beginners Guide: Humanized Drug Target Immuno-Oncology Models Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ... LEARN MORE
September 14, 2017 First Type 2 Diabetes Publication Comparing Pros and Cons of Two Preclinical Continuous Glucose Monitoring Systems Significant Correlation between Blood Glucose Levels Measured by Glucometer and both the Dexcom G4 Platinum and HD-XG ... LEARN MORE
September 12, 2017 CD137: An Important Target in T Cell Co-Stimulation Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell co-stimulation. LEARN MORE
September 7, 2017 When to Use Stable vs Transiently Humanized I/O Models As immunotherapeutics continue to dominate oncology headlines and research, more preclinical studies are requiring ... LEARN MORE
September 5, 2017 Treatment Approaches for EGFR-Mutated Lung Cancer Each year, around 140,000 people worldwide (15,000 in the United States alone) are diagnosed with epidermal growth ... LEARN MORE
August 31, 2017 Recent Type 2 Diabetes Publication Demonstrates Preclinical Study Benefits of Continuous Glucose Monitoring Daily Blood Glucose Fluctuations in Normal and Diabetic NHPs from Wang et al. J Endocrinol Invest 2017;40(9): 967-977. ... LEARN MORE
August 29, 2017 OX40 Agonists: Boosting Cancer Immunotherapy Following our recent post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take a closer look at specific family members important in immuno-oncology. First up is the OX40 receptor and its binding partner OX40-Ligand (OX40L). LEARN MORE
August 24, 2017 Mouse Allograft Models: A GEMM-Derived Efficacy Testing Platform Genetically engineered mouse models (GEMM) were reviewed in a recent post, as immunocompetent, murine immunity models ... LEARN MORE
August 22, 2017 The Beginners Guide to Neoantigens and Immuno-Oncology Studies \Neoantigens are mutation associated antigens that arise from nonsynonomous somatic variations acquired in tumors ... LEARN MORE
August 17, 2017 How to Optimize your Non GLP Toxicology Studies Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical ... LEARN MORE
August 15, 2017 Genetically Engineered Mouse Models (GEMM) for I/O Studies Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ... LEARN MORE